Teplizumab works by binding to a part of the immune system’s T cells called the CD3 receptor, which effectively reprograms the T cells that are attacking insulin-producing beta cells in the pancreas. Rather than broadly suppressing the immune system, teplizumab nudges specific populations of destructive T cells into a state of “exhaustion,” where they lose their ability to cause damage. This targeted mechanism is what made it the first drug approved by the FDA to delay the onset of type 1 diabetes, and the science behind how it accomplishes this is more layered than a simple on-off switch.
Binding to CD3 on the T-Cell Surface
Every T cell in your body carries a structure called the T-cell receptor complex, which includes a component known as CD3. Think of CD3 as the signaling antenna that tells the T cell what to do when it encounters something it recognizes. Teplizumab is a monoclonal antibody engineered to latch onto one specific piece of that antenna, the CD3ε (epsilon) chain. When it does, the normal signaling that would activate the T cell gets disrupted. The drug binds with relatively moderate affinity, which turns out to be important for its safety profile.
Teplizumab is actually a redesigned version of an older drug called OKT3 (muromonab-CD3), which was the first monoclonal antibody ever approved for use in humans, back in 1986, for preventing organ transplant rejection. OKT3 worked by the same basic principle of targeting CD3, but it came with severe side effects. When OKT3 latched onto T cells, it triggered a massive inflammatory reaction, sometimes called “cytokine storm,” because the drug’s Fc region (the tail end of the antibody) aggressively engaged immune cell receptors and caused widespread T-cell activation before shutting them down. That made it effective but dangerous.
How Fc Engineering Changed Everything
The critical difference between teplizumab and its predecessor comes down to two small amino acid swaps in the antibody’s Fc region. Engineers replaced two leucine residues with alanine, which dramatically reduced the antibody’s ability to bind to Fc receptors on other immune cells. The practical result was striking: T-cell activation, proliferation, and cytokine release all dropped by a factor of roughly 100 to 1,000 compared with OKT3.1PubMed Central. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function This is why teplizumab can modulate T-cell behavior without triggering the dangerous inflammatory cascade that plagued its predecessor.
The Fc modifications mean teplizumab sends a much quieter signal through the T-cell receptor complex. Instead of the aggressive “activate then destroy” approach of OKT3, teplizumab delivers a partial signal that steers T cells toward exhaustion rather than death. That distinction matters because the goal in type 1 diabetes is not to wipe out the patient’s entire T-cell population but to specifically dial down the ones causing harm.
Pushing T Cells Toward Exhaustion
The centerpiece of teplizumab’s mechanism is something immunologists call “partial exhaustion” of T cells. In normal immune responses, T cells that are chronically stimulated without resolution, as happens during long-term viral infections or cancer, eventually enter a tired, less functional state. They stop proliferating as aggressively, lose some of their killing ability, and start expressing molecular markers that act like brakes on the surface. Teplizumab essentially fast-tracks this process in the T cells that are attacking the pancreas.
In patients who respond well to teplizumab, researchers have identified a specific population of CD8 T cells (the “killer” T cells responsible for destroying beta cells) that accumulate after treatment. These cells express high levels of a transcription factor called EOMES and carry multiple inhibitory receptors on their surface, including TIGIT and KLRG1. Their levels peak around three to six months after treatment.2PubMed Central. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes The more of these exhausted cells a patient develops, the better their clinical outcome tends to be.
Detailed tracking of immune cell populations during treatment shows what happens in real time. The first 14-day course of teplizumab reduces CD4 T cells, CD8 T cells, regulatory T cells, and natural killer T cells by roughly 35 to 60 percent immediately after infusion. All of these populations bounce back to their pre-treatment levels within about two months. But something shifts in the composition of those returning cells: the percentage of partially exhausted KLRG1+TIGIT+ CD8 T cells increases within two months and stays elevated for approximately nine months after each course.3PubMed Central. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes So the overall number of T cells returns to normal, but a meaningful fraction of those reconstituted cells are now in a dampened, less destructive state.
What Happens Inside the Pancreas
Most of the human data on teplizumab comes from blood samples, but animal studies using the equivalent anti-CD3 antibody have provided a window into what happens at the tissue level. In mouse models of autoimmune diabetes, treatment reshapes the T cells that have infiltrated the pancreatic islets. Autoantigen-specific CD8 T cells, the ones trained to recognize and destroy beta cells, show dramatically reduced expression of granzyme B, a key molecule they use to punch holes in their targets.4JCI Insight. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes In other words, the destructive T cells are still physically present in the pancreas after treatment, but they have been functionally disarmed.
This local disarmament is distinct from what a broadly immunosuppressive drug would accomplish. A general immunosuppressant might clear the islets of all immune cells, leaving the patient vulnerable to infections. Teplizumab’s approach is more surgical: it leaves the architectural framework of the immune response intact while changing the character of the cells within it.
Effects on Regulatory T Cells
The exhaustion of killer T cells is only half the story. Teplizumab also appears to boost the regulatory side of the immune system. Regulatory T cells are the immune system’s peacekeepers, responsible for preventing other immune cells from attacking the body’s own tissues. In patients treated with teplizumab, a specific subset of regulatory cells that express a gut-homing marker called CCR6 showed increased production of IL-10, an anti-inflammatory signaling molecule.5PubMed Central. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients
The fact that these regulatory cells express gut-homing markers is intriguing because the gut-associated lymphoid tissue is one of the largest immune compartments in the body and plays an outsized role in shaping immune tolerance. The expansion of gut-tropic regulatory cells after teplizumab treatment hints that the drug may be resetting some of the immune tolerance machinery that breaks down in people who develop type 1 diabetes. This dual action, damping destructive cells while amplifying protective ones, helps explain why the drug’s effects can persist well beyond the two-week infusion period.
Preserving Beta-Cell Function
All of this immune reprogramming serves one practical goal: keeping the remaining insulin-producing beta cells alive long enough that the patient retains some of their own insulin production. The standard way to measure this is through C-peptide levels, a molecule released in equal amounts to insulin that serves as a reliable marker of how much insulin the pancreas is still making.
In people with newly diagnosed type 1 diabetes, teplizumab consistently preserves C-peptide levels better than placebo. A large trial found that at 78 weeks, about 95 percent of teplizumab-treated patients maintained a clinically meaningful peak C-peptide level, compared with roughly 79 percent on placebo.6PubMed. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes A systematic review and meta-analysis of randomized trials in stage 3 type 1 diabetes confirmed this pattern, showing improved C-peptide preservation at 9 to 15 months along with reductions in daily insulin requirements and HbA1c levels.7PubMed Central. The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
In people who have not yet progressed to clinical diabetes but are at high risk (stage 2, where autoantibodies are present and blood sugar is starting to become abnormal), teplizumab actually reversed a decline in beta-cell function that had been occurring before enrollment. The drug improved average C-peptide levels compared with placebo and stabilized what had been a downward trajectory.8PubMed Central. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals Even more compelling, the integrated analysis of patients treated with one or two courses showed that the C-peptide benefit grew over time, with the advantage over placebo being larger at year two than at year one.9PubMed Central. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function
Delaying the Onset of Clinical Diabetes
The landmark finding that led to teplizumab’s approval was its ability to delay progression from stage 2 to stage 3 type 1 diabetes. In the pivotal trial, a single 14-day course pushed the median time to diabetes diagnosis from about 24 months with placebo to over 48 months with teplizumab. The annualized rate of progression dropped from roughly 36 percent per year to 15 percent per year, and the overall risk of progressing was cut by nearly 60 percent.10PubMed Central. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review
Those extra two or more years without clinical diabetes matter enormously, particularly for children and adolescents who are the most common age group affected. Every year of delay is a year without the daily burden of insulin management, a year of continued pancreatic function, and a year of potential improvements in the broader treatment landscape.
How Long the Effects Last
One question that looms over any immune-modulating therapy is whether the benefits persist or fade. Follow-up data out to seven years after diagnosis in people who initially responded to teplizumab showed reduced decline in C-peptide and persistent immunological changes compared with non-responders.11PubMed Central. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis The immune signature induced by teplizumab, the expanded population of exhausted CD8 T cells, appears to be self-sustaining to some degree, though it does diminish over time.
The transient nature of the initial lymphocyte drop (recovery within about two months, as noted earlier) combined with the longer persistence of the exhausted T-cell phenotype (around nine months per course) suggests a treatment window where re-dosing could reinforce the effect.12PubMed Central. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes In the clinical trials testing two courses given a year apart, the second course produced reductions in T-cell numbers similar to the first, and the exhausted phenotype was re-expanded. This is encouraging because it means the immune system does not appear to develop resistance to the drug’s effects with repeat dosing.
Not Everyone Responds the Same Way
A consistent challenge with teplizumab is that not all patients benefit equally. Some people show dramatic preservation of beta-cell function and delayed disease progression, while others progress despite treatment. Researchers have been working to identify biomarkers that could predict who will respond before treatment begins.
Early work on metabolic profiling has identified a set of baseline blood metabolites that differ between responders and non-responders. People who go on to respond well tend to have higher baseline levels of certain metabolites linked to the citric acid cycle, specific amino acids, and certain microbial byproducts. Non-responders, by contrast, tend to have higher baseline levels of glutamate. A machine-learning model built on these metabolite signatures achieved an accuracy of about 77 percent and a high area under the curve in distinguishing the two groups.13medRxiv. Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes This is still early-stage work from a preprint, and these metabolite panels are not yet ready for clinical use, but they point toward a future where treatment decisions could be guided by a simple blood test.
The immunological marker most consistently linked to good outcomes is the accumulation of those partially exhausted CD8 T cells described earlier. Patients whose blood shows a robust expansion of KLRG1+TIGIT+ CD8 T cells after treatment tend to have better C-peptide preservation. This creates a somewhat circular situation for prediction, since you only see the marker after treatment has started, but it does provide a useful early readout for clinicians monitoring whether the drug is taking effect in a given patient.
Teplizumab in Young Children
The original approval of teplizumab covered patients aged eight and older with stage 2 type 1 diabetes. But type 1 diabetes often strikes much younger children, and there has been particular concern about whether the drug is safe and effective in that age group. A study evaluating teplizumab in children under eight with stage 2 disease found that the drug’s pharmacokinetics and safety profile were consistent with what had been observed in older patients. At interim analysis, the estimated probability of not progressing to stage 3 diabetes was about 90 percent.14PubMed Central. Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes A transient decrease in lymphocyte count, which is an expected and reversible pharmacological effect of the drug’s mechanism, was observed in this younger population as well.
The stakes of disease delay are arguably highest in very young children, where the management burden of insulin therapy falls on parents and the risks of both hyperglycemia and hypoglycemia can be particularly difficult to control. Whether the immune system of a young child responds differently to teplizumab in the long run remains an open question, since the pediatric immune system is still maturing and may either be more susceptible to reprogramming or more capable of bouncing back to a pre-treatment state.
Combination Therapy Approaches
Because teplizumab addresses only the T-cell arm of the autoimmune attack, researchers have been exploring whether pairing it with other agents could produce additive or synergistic benefits. One early-stage trial combined teplizumab with AG019, an oral capsule containing engineered bacteria that deliver proinsulin and an immune-modulating cytokine directly to the gut-associated immune tissue. In participants who received the combination, all measured metabolic variables stabilized or improved over 12 months, and the expansion of partially exhausted CD8 T cells at six months was significantly greater than with either agent alone.15PubMed Central. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
The logic behind combining teplizumab with antigen-specific therapies is appealing. Teplizumab can create a window of immune vulnerability by exhausting the pathogenic T cells, and an antigen-specific therapy delivered during that window might train the immune system to tolerate the beta-cell proteins it was previously attacking. This “reset and retrain” concept is being explored in several ongoing trials, though none have yet produced the definitive large-scale data needed to change clinical practice.
The Cost Question
Teplizumab’s list price has drawn scrutiny. The drug is administered as a 14-day intravenous infusion, requiring daily clinic or infusion center visits, which adds facility and staffing costs on top of the drug price itself. Economic modeling has acknowledged that the potentially high cost may create challenges for insurance coverage and reimbursement.16PubMed. Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups The counterargument from a health-economics perspective is that delaying the onset of type 1 diabetes by even two years avoids the cumulative costs of insulin, continuous glucose monitoring, clinic visits, and hospitalizations for diabetic emergencies. For a child who might otherwise be diagnosed at age ten, pushing that to age twelve or beyond represents a meaningful reduction in lifetime diabetes management costs.
Access is further complicated by the fact that the drug is currently approved only for stage 2 type 1 diabetes, which requires screening with islet autoantibody panels and oral glucose tolerance testing to identify. Most people with stage 2 disease do not yet know they have it, because universal screening for type 1 diabetes risk is not standard practice in most countries. Expanding screening programs would increase the pool of people who could benefit from teplizumab, but it would also increase the total expenditure on the drug, creating a tension that health systems are still working through.
How Teplizumab Differs From General Immunosuppression
A common misconception is that teplizumab “suppresses the immune system” the way transplant drugs do. The distinction matters for how patients and clinicians think about the drug’s risks. Conventional immunosuppressants like cyclosporine or tacrolimus broadly dampen the immune response and must be taken continuously, leaving patients vulnerable to infections and cancers over time. Teplizumab is given as a short course, after which the immune system returns to essentially normal numbers and function for fighting infections. What changes is the behavior of a specific subset of T cells, not the immune system’s overall capacity.
The transient lymphocyte drop during the infusion period does temporarily increase infection susceptibility, and the most common side effects during treatment are lymphopenia, rash, and headache. But these resolve after the infusion course ends, and the long-term safety data have not shown increased rates of serious infections or malignancies. This favorable safety profile is a direct consequence of the Fc engineering that dialed down the inflammatory signaling and the mechanism’s reliance on steering T cells rather than eliminating them.